Georg Beyer
A5068096506- Pancreatitis Pathology and Treatment
- Pancreatic and Hepatic Oncology Research
- Gastrointestinal disorders and treatments
- Liver Disease Diagnosis and Treatment
- IgG4-Related and Inflammatory Diseases
- Cancer Genomics and Diagnostics
- Neuroendocrine Tumor Research Advances
- Gallbladder and Bile Duct Disorders
- Phagocytosis and Immune Regulation
- Renal cell carcinoma treatment
- Pediatric Hepatobiliary Diseases and Treatments
- Diabetes and associated disorders
- Cancer Immunotherapy and Biomarkers
- Caveolin-1 and cellular processes
- Peptidase Inhibition and Analysis
- Cancer Diagnosis and Treatment
- Natural Compounds in Disease Treatment
- Pharmacological Effects and Toxicity Studies
- Glioma Diagnosis and Treatment
- Abdominal vascular conditions and treatments
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Immune cells in cancer
- Appendicitis Diagnosis and Management
- Intestinal Malrotation and Obstruction Disorders
- Cancer-related gene regulation
Ludwig-Maximilians-Universität München
2017-2024
LMU Klinikum
2017-2024
Bielefeld University
2021-2024
Universitätsmedizin Greifswald
2012-2022
Leipzig University
2022
Evangelisches Krankenhaus Bielefeld
2021
University Hospital Münster
2014-2018
University of Münster
2014-2018
University Hospital of Zurich
2018
Universität Greifswald
2013-2017
Schlüsselwörter akute Pankreatitis - chronische Schmerztherapie Diagnose Therapie Epidemiologie Klassifizierung Autoimmune
Objective Changes of the pancreaticobiliary ducts herald disease. Magnetic resonance cholangiopancreatography (MRCP) allows accurate duct visualisation. Data on reliable upper reference ranges are missing. Design Cross-sectional whole body MRI data from population-based Study Health in Pomerania were analysed. The width common bile (CBD) and pancreatic (PD) was determined. We aimed to describe distribution physiological diameters MRCP a population healthy subjects identify factors...
Background and aims Autoimmune pancreatitis (AIP) is an immune-mediated disease of the pancreas with distinct pathophysiology manifestations. Our were to characterize type 1 AIP in a large pan-European cohort study effectiveness current treatment regimens. Methods We retrospectively analyzed adults diagnosed since 2005 or not-otherwise-specified 42 European university hospitals. Type was uniformly using specific diagnostic criteria. Patients 2 those who had undergone pancreatic surgery...
Objective Early disease prediction is challenging in acute pancreatitis (AP). Here, we prospectively investigate whether the microbiome predicts severity of AP (Pancreatitis—Microbiome As Predictor Severity; P-MAPS) early at hospital admission. Design Buccal and rectal microbial swabs were collected from 424 patients with within 72 hours admission 15 European centres. All samples sequenced by full-length 16S rRNA metagenomic sequencing using Oxford Nanopore Technologies. Primary endpoint was...
Objective Chronic pancreatitis (CP) is a fibroinflammatory syndrome leading to organ dysfunction, chronic pain, an increased risk for pancreatic cancer and considerable morbidity. Due lack of specific biomarkers, diagnosis based on symptoms but insensitive imaging features, preventing early appropriate management. Design We conducted type 3 study multivariable prediction individual prognosis according the TRIPOD guidelines. A signature distinguish CP from controls (n=160) was identified...
In pancreatic cancer, systemic treatment options in addition to chemotherapy remain scarce, and so far only a small proportion of patients benefit from targeted therapies.The with cancer discussed the CCCMunichLMU Molecular Tumor Board were reviewed gain better real-world understanding challenges chances precision oncology this hard-to-treat cancer.Patients who received comprehensive genomic profiling interdisciplinary between May 2017 July 2022 included. These patients' medical charts,...
Fluoropyrimidine c (5-fluorouracil [5FU]) increasingly represents the chemotherapeutic backbone for neoadjuvant, adjuvant, and palliative treatment of pancreatic ductal adenocarcinoma (PDAC). Even in combination with other agents, 5FU efficacy remains transient limited. One explanation inadequate response is insufficient nonspecific delivery to tumor.
Pancreatic ductal adenocarcinoma cancer (PDAC) is a highly lethal malignancy requiring efficient detection when the primary tumor still resectable. We previously developed MxPancreasScore comprising 9 analytes and serum carbohydrate antigen 19-9 (CA19-9), achieving an accuracy of 90.6%. The necessity for 5 different analytical platforms multiple runs, however, hindered clinical applicability. therefore aimed to develop simpler single-analytical run, single-platform diagnostic signature.We...
Despite evidence-based guidelines, exocrine pancreatic insufficiency is frequently underdiagnosed and undertreated in patients with chronic pancreatitis. Therefore, the aim of this study to provide insight into current opinion clinical decision-making international pancreatologists regarding management insufficiency. An online survey case vignette was sent experts pancreatitis members various associations: EPC, E-AHPBA DPSG. Experts were selected based on publication record from past 5...